Security
Haemonetics Corporation · HAE
HAENYSECommon stockCurrentCIK 313143Updated Oct 9, 2026
HAE price & chart
Loading TradingView…
NYSE:HAE on TradingView ↗About the company
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
In the news
Haemonetics Acquires Vivasure Medical Limited News provided by Haemonetics Corporation Jan 09, 2026, 06:15 ET Share this article Share to X Share this article Share to X BOSTON , Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE ), a global medical technology company focused on deliver ↗
Recent filings
Regulation FD Disclosure
Items 7.01
Regulation FD Disclosure
Items 7.01
SCHEDULE 13G/A - filed by AQR CAPITAL MANAGEMENT LLC regarding HAEMONETICS CORP
S-8 filing
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
ARS filing
DEFA14A filing
DEF 14A filing
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 2,490,890,000Source | 2,531,270,000Source | 2,200,428,000Source | 2,442,156,000Source | 2,525,224,000Source | 2,365,400,000Source | 2,462,094,000Source | 2,540,977,000Source | 2,395,925,000Source | 2,450,948,000Source | 2,195,591,000Source | 1,934,825,000Source |
| Property, Plant and Equipment, NetUSD | 297,234,000Source | 286,107,000Source | 318,665,000Source | 292,476,000Source | 300,478,000Source | 303,778,000Source | 286,865,000Source | 302,480,000Source | 305,761,000Source | 284,052,000Source | 311,362,000Source | 310,885,000Source |
| GoodwillUSD | 606,825,000Source | 605,266,000Source | 554,999,000Source | 606,101,000Source | 616,162,000Source | 656,884,000Source | 607,299,000Source | 613,347,000Source | 656,368,000Source | 604,269,000Source | 565,082,000Source | 466,231,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 419,734,000Source | 465,615,000Source | 429,270,000Source | 428,357,000Source | 487,837,000Source | 434,512,000Source | 450,634,000Source | 494,935,000Source | 447,655,000Source | 455,743,000Source | 406,117,000Source | 275,771,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 363,367,000Source | 320,846,000Source | 193,978,000Source | 296,426,000Source | 299,283,000Source | 223,384,000Source | 292,898,000Source | 344,429,000Source | 245,440,000Source | 306,763,000Source | 178,800,000Source | 284,466,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 195,707,000Source | 211,949,000Source | 211,611,000Source | 207,066,000Source | 213,534,000Source | 216,071,000Source | 200,752,000Source | 201,485,000Source | 216,855,000Source | 202,657,000Source | 206,562,000Source | 179,142,000Source |
| Inventory, NetUSD | 321,185,000Source | 359,614,000Source | 304,024,000Source | 336,206,000Source | 382,105,000Source | 306,739,000Source | 360,527,000Source | 373,787,000Source | 306,370,000Source | 365,141,000Source | 317,202,000Source | 259,379,000Source |
| Assets, CurrentUSD | 943,674,000Source | 1,005,868,000Source | 764,982,000Source | 899,682,000Source | 955,902,000Source | 810,832,000Source | 913,160,000Source | 978,578,000Source | 834,879,000Source | 934,975,000Source | 768,903,000Source | 769,722,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 63,415,000Source | 113,459,000Source | 55,369,000Source | 59,984,000Source | 60,980,000Source | 64,638,000Source | 58,983,000Source | 58,877,000Source | 66,214,000Source | 60,414,000Source | 66,339,000Source | 46,735,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | 39,619,000Source | 47,492,000Source | 55,268,000Source | 53,413,000Source |
| Other Assets, NoncurrentUSD | 216,094,000Source | 160,414,000Source | 127,442,000Source | 207,969,000Source | 155,762,000Source | 149,960,000Source | 196,293,000Source | 142,268,000Source | 141,741,000Source | 164,106,000Source | 136,388,000Source | 106,975,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 468,000Source | 502,000Source | 508,000Source | 467,000Source | 504,000Source | 455,000Source | 482,000Source | 512,000Source | 453,000Source | 482,000Source | 508,000Source | 504,000Source |
| Retained Earnings (Accumulated Deficit)USD | 381,091,000Source | 392,230,000Source | 340,099,000Source | 336,323,000Source | 368,536,000Source | 311,516,000Source | 356,046,000Source | 386,642,000Source | 279,344,000Source | 352,174,000Source | 360,456,000Source | 253,168,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -34,610,000Source | -55,501,000Source | -24,382,000Source | -40,531,000Source | -34,564,000Source | -41,629,000Source | -36,242,000Source | -42,667,000Source | -37,614,000Source | -55,084,000Source | -35,632,000Source | -30,381,000Source |
| Stockholders' Equity Attributable to ParentUSD | 911,451,000Source | 906,860,000Source | 943,319,000Source | 849,173,000Source | 878,851,000Source | 837,101,000Source | 882,300,000Source | 905,368,000Source | 796,320,000Source | 820,836,000Source | 959,959,000Source | 817,997,000Source |
| Additional Paid in Capital, Common StockUSD | 564,502,000Source | 569,629,000Source | 627,094,000Source | 552,914,000Source | 544,375,000Source | 566,759,000Source | 562,014,000Source | 560,881,000Source | 554,137,000Source | 523,264,000Source | 634,627,000Source | 594,706,000Source |
| Liabilities and EquityUSD | 2,490,890,000Source | 2,531,270,000Source | 2,200,428,000Source | 2,442,156,000Source | 2,525,224,000Source | 2,365,400,000Source | 2,462,094,000Source | 2,540,977,000Source | 2,395,925,000Source | 2,450,948,000Source | 2,195,591,000Source | 1,934,825,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 539,868,000Source | 253,233,000Source | 261,755,000Source | 548,318,000Source | 273,946,000Source | 263,235,000Source | 531,407,000Source | 260,076,000Source | 282,599,000Source | 578,113,000Source | 300,383,000Source | 251,816,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 9,243,000Source | 8,107,000Source | 8,133,000Source | 7,162,000Source |
| Accounts Payable, CurrentUSD | 48,694,000Source | 62,990,000Source | 56,845,000Source | 61,691,000Source | 69,242,000Source | 56,338,000Source | 46,010,000Source | 76,929,000Source | 51,056,000Source | 66,999,000Source | 73,358,000Source | 63,929,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | 40,898,000Source | 50,454,000Source | 57,958,000Source | 55,903,000Source |
| Deferred Income Tax Liabilities, NetUSD | 55,979,000Source | 61,451,000Source | 62,246,000Source | 58,201,000Source | 62,893,000Source | 38,691,000Source | 59,488,000Source | 64,793,000Source | 38,048,000Source | 62,575,000Source | 62,644,000Source | 36,195,000Source |
| Other Liabilities, NoncurrentUSD | 63,605,000Source | 89,964,000Source | 76,259,000Source | 66,071,000Source | 90,011,000Source | 57,171,000Source | 68,066,000Source | 92,263,000Source | 59,393,000Source | 68,194,000Source | 75,041,000Source | 74,715,000Source |
| Additional Financial Items | ||||||||||||
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD | — | — | — | — | — | — | — | — | 746,000Source | -1,149,000Source | -1,748,000Source | -4,075,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 28,527,000Source | 54,772,000Source | 54,905,000Source | 30,954,000Source |
| Long-term Debt, Current MaturitiesUSD | 304,746,000Source | 5,075,000Source | 13,736,000Source | 304,335,000Source | 5,434,000Source | 4,956,000Source | 303,949,000Source | 5,109,000Source | 5,015,000Source | 303,558,000Source | 10,229,000Source | 11,784,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 919,987,000Source | 1,219,762,000Source | 856,849,000Source | 920,393,000Source | 1,219,523,000Source | 1,169,202,000Source | 920,833,000Source | 1,218,477,000Source | 1,219,565,000Source | 921,230,000Source | 797,564,000Source | 754,102,000Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 9,311,000Source | 9,312,000Source | 33,827,000Source | 29,636,000Source | 28,332,000Source | 25,583,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -297,000Source | -3,557,000Source | 14,881,000Source | -6,956,000Source | 24,193,000Source | 24,421,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 1,004,000Source | -3,296,000Source | -47,361,000Source | 64,704,000Source | 60,061,000Source | -30,754,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 668,000Source | -3,231,000Source | -26,401,000Source | -5,623,000Source | -10,877,000Source | 5,777,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 52,323,000Source | 17,395,000Source | 293,221,000Source | 181,725,000Source | 181,751,000Source | 273,058,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | 0Source | 60,180,000Source | 150,906,000Source | 243,852,000Source | 2,850,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -22,234,000Source | -33,000,000Source | -179,547,000Source | -161,895,000Source | -322,389,000Source | -143,788,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 7,906,000Source | 3,754,000Source | 32,780,000Source | 39,278,000Source | 66,296,000Source | 110,191,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 3,500,000Source | 4,781,000Source | 5,001,000Source | 10,243,000Source | 5,885,000Source | — |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | 175,000,000Source | 225,000,000Source | 0Source | 75,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -51,528,000Source | -2,442,000Source | -178,460,000Source | 108,818,000Source | 38,157,000Source | -100,364,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | -14,000Source | -36,000Source | -102,000Source | -249,000Source | -73,000Source | -44,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 1,563,000Source | 1,563,000Source | — | 4,688,000Source | 12,250,000Source | 9,625,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -22,056,000Source | -13,865,000Source | -61,323,000Source | 127,963,000Source | -105,666,000Source | 24,970,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 363,367,000Source | 320,846,000Source | 296,426,000Source | 299,283,000Source | 223,384,000Source | 292,898,000Source | 245,440,000Source | 306,763,000Source | 178,800,000Source | 284,466,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 17,465,000Source | 16,534,000Source | 20,901,000Source | 13,587,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 60,665,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -617,000Source | 4,182,000Source | 3,463,000Source | -685,000Source | -3,185,000Source | -3,936,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 7,799,000Source | 8,214,000Source | 7,589,000Source | 6,857,000Source | — | 9,312,000Source | 33,827,000Source | 29,636,000Source | 28,332,000Source | 25,583,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | 3,175,000Source | 1,970,000Source |
| Amortization of Intangible AssetsUSD | — | — | 12,400,000Source | 13,900,000Source | 12,800,000Source | 14,200,000Source | 11,800,000Source | 13,300,000Source | 50,500,000Source | 55,600,000Source | 41,400,000Source | 42,100,000Source |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | — | 6,100,000Source | 6,700,000Source | 8,600,000Source | 8,500,000Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -26,471,000Source | -5,219,000Source | -11,039,000Source | 4,783,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | — | — | — | — | — | — | — | — | -15,000Source | 104,000Source | 0Source | 330,000Source |
| DepreciationUSD | — | — | 14,900,000Source | 15,200,000Source | 15,500,000Source | 15,000,000Source | 15,400,000Source | 15,400,000Source | 61,200,000Source | 60,000,000Source | 55,800,000Source | 51,200,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | — | 2,000,000Source | 382,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -3,200,000Source | -900,000Source | -4,000,000Source | -1,000,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | 0Source | — | 0Source | — | — | — | — | -2,000,000Source | -382,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 243,000Source | 714,000Source | 15,698,000Source | — | — |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 6,670,000Source | 5,230,000Source |
| GoodwillUSD | — | — | 606,825,000Source | 605,266,000Source | 606,101,000Source | 616,162,000Source | 656,884,000Source | 607,299,000Source | 656,368,000Source | 604,269,000Source | 565,082,000Source | 466,231,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | 716,000Source | 0Source | — | — | — | — | — | — | 10,419,000Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | — | — | 0Source | 0Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | 0Source | — | 2,391,000Source | — | — | 86,546,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 15,235,000Source | 12,423,000Source | 12,601,000Source | 10,873,000Source | 14,564,000Source | 11,138,000Source | 30,722,000Source | 44,392,000Source | 34,307,000Source | 26,002,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 44,740,000Source | 37,494,000Source | 38,684,000Source | 33,831,000Source | 33,010,000Source | 34,031,000Source | 97,308,000Source | 167,679,000Source | 117,558,000Source | 115,401,000Source |
| Operating ExpensesUSD | — | — | 134,990,000Source | 134,518,000Source | 136,253,000Source | 135,740,000Source | 145,345,000Source | 138,372,000Source | 630,852,000Source | 527,141,000Source | 526,665,000Source | 459,064,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,421,000Source | -9,112,000Source | -7,206,000Source | -6,993,000Source | -9,884,000Source | -8,703,000Source | -28,704,000Source | -9,746,000Source | -13,018,000Source | -14,630,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 426,000Source | 462,000Source | — | — | 1,610,000Source | 2,638,000Source |
| Restructuring CostsUSD | — | — | — | -3,515,000Source | — | -4,792,000Source | — | — | — | — | 14,089,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 338,967,000Source | 348,542,000Source | 327,315,000Source | 345,511,000Source | 339,380,000Source | 321,394,000Source | 1,334,027,000Source | 1,360,824,000Source | 1,309,055,000Source | 1,168,660,000Source |
| Income (Loss) from Equity Method Investments | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Payments to Acquire Investments | — | — | — | — | — | —Source | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 338,967,000Source | 348,542,000Source | 327,315,000Source | 345,511,000Source | 339,380,000Source | 321,394,000Source | 1,334,027,000Source | 1,360,824,000Source | 1,309,055,000Source | — |
| Cost of RevenueUSD | — | — | 136,581,000Source | 154,995,000Source | 132,571,000Source | 158,074,000Source | 136,577,000Source | 129,150,000Source | 546,441,000Source | 611,866,000Source | 617,507,000Source | 553,563,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 109,154,000Source | 106,459,000Source | 101,615,000Source | 106,946,000Source | 118,941,000Source | 110,719,000Source | 442,421,000Source | 436,789,000Source | 431,780,000Source | 376,675,000Source |
| Operating Income (Loss)USD | — | — | 67,396,000Source | 59,029,000Source | 58,491,000Source | 51,697,000Source | 57,458,000Source | 53,872,000Source | 156,734,000Source | 221,817,000Source | 164,883,000Source | 156,033,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,421,000Source | -9,112,000Source | -7,206,000Source | -6,993,000Source | -9,884,000Source | -8,703,000Source | -28,704,000Source | -9,746,000Source | -13,018,000Source | -14,630,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 59,975,000Source | 49,917,000Source | 51,285,000Source | 44,704,000Source | 47,574,000Source | 45,169,000Source | 128,030,000Source | 212,071,000Source | 151,865,000Source | 141,403,000Source |
| Income Tax Expense (Benefit)USD | — | — | 15,235,000Source | 12,423,000Source | 12,601,000Source | 10,873,000Source | 14,564,000Source | 11,138,000Source | 30,722,000Source | 44,392,000Source | 34,307,000Source | 26,002,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 44,740,000Source | 37,494,000Source | 38,684,000Source | 33,831,000Source | 33,010,000Source | 34,031,000Source | 97,308,000Source | 167,679,000Source | 117,558,000Source | 115,401,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.96Source | 0.75Source | 0.81Source | 0.66Source | 0.73Source | 0.71Source | 2.06Source | 3.33Source | 2.32Source | 2.27Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.95Source | 0.74Source | 0.81Source | 0.66Source | 0.72Source | 0.7Source | 2.05Source | 3.31Source | 2.29Source | 2.24Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 46,792,000Source | 50,286,000Source | 47,590,000Source | 50,898,000Source | 45,361,000Source | 48,111,000Source | 47,179,000Source | 50,330,000Source | 50,706,000Source | 50,783,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 46,987,000Source | 50,639,000Source | 47,664,000Source | 51,240,000Source | 45,704,000Source | 48,353,000Source | 47,354,000Source | 50,730,000Source | 51,397,000Source | 51,420,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 12,400,000Source | 13,900,000Source | 12,800,000Source | 14,200,000Source | 11,800,000Source | 13,300,000Source | 50,500,000Source | 55,600,000Source | 41,400,000Source | 42,100,000Source |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | — | 6,100,000Source | 6,700,000Source | 8,600,000Source | 8,500,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 57,123,000Source | 50,015,000Source | 45,184,000Source | 20,225,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | — | — | — | — | — | — | — | — | -15,000Source | 104,000Source | 0Source | 330,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 27,385,000Source | 29,025,000Source | 28,255,000Source | 29,217,000Source | 27,111,000Source | 28,758,000Source | 111,717,000Source | 115,586,000Source | 97,215,000Source | 93,307,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -3,200,000Source | -900,000Source | -4,000,000Source | -1,000,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | 0Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 6,670,000Source | 5,230,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | — | — | 0Source | 0Source | — |
| Gross ProfitUSD | — | — | 202,386,000Source | 193,547,000Source | 194,744,000Source | 187,437,000Source | 202,803,000Source | 192,244,000Source | 787,586,000Source | 748,958,000Source | 691,548,000Source | 615,097,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 87,236,000Source | 161,800,000Source | 112,563,000Source | 85,657,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | 19,300,000Source | 35,900,000Source | 19,500,000Source | 13,000,000Source |
| Operating ExpensesUSD | — | — | 134,990,000Source | 134,518,000Source | 136,253,000Source | 135,740,000Source | 145,345,000Source | 138,372,000Source | 630,852,000Source | 527,141,000Source | 526,665,000Source | 459,064,000Source |
| Research and Development ExpenseUSD | — | — | 14,187,000Source | 15,829,000Source | 14,872,000Source | 14,139,000Source | 16,200,000Source | 16,261,000Source | 59,766,000Source | 62,722,000Source | 54,435,000Source | 50,131,000Source |
| Restructuring CostsUSD | — | — | — | -3,515,000Source | — | -4,792,000Source | — | — | — | — | 14,089,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 338,967,000Source | 348,542,000Source | 327,315,000Source | 345,511,000Source | 339,380,000Source | 321,394,000Source | 1,334,027,000Source | 1,360,824,000Source | 1,309,055,000Source | 1,168,660,000Source |
| Income (Loss) from Equity Method Investments | — | — | — | — | — | — | —Source | — | — | — | — | — |
Filing attachments
ex991-fy27q1earningsrelease.htm · 8-K · 2026-08-06
EX-99.1 2 ex991-fy27q1earningsrelease.htm EX-99.1 Document Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@…
Read attachment ↗ex991-pressrelease652026.htm · 8-K · 2026-06-05
Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President - Investor Relations & Treasury Josh Gitelson, Sr. Director - Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Sr. Manager - Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemone…
Read attachment ↗ex991-q4mar2026earningsrel.htm · 8-K · 2026-05-07
Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director- Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations …
Read attachment ↗ea027953601ex99-1.htm · SCHEDULE 13G · 2026-03-03
Exhibit 99.1 JOINT FILING AGREEMENT March 3, 2026 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with the Securities …
Read attachment ↗ex991-fy26q3decearningsrel.htm · 8-K · 2026-02-05
Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Third Quart…
Read attachment ↗ex991-pressrelease192026.htm · 8-K · 2026-01-09
Exhibit 99.1 Investor Contacts: Olga Guyette, VP-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 olga.guyette@haemonetics.com david.trenk@haemonetics.com Media Contact: Josh Gitelson, Senior Director-Global Communications (781) 356-9776 josh.gitelson@haemonetics.com Haemonetics Acquires Vivasure Medical Limited BOSTON, MA, January 9, 2026 -- Ha…
Read attachment ↗